PYN Phynova

RNS Number:9451I
Phynova Group PLC
03 December 2007


For Immediate Release                                         3 December 2007



                               Phynova Group plc



                                  ("Phynova")



              Plant-derived antibacterial PYN6 active against MRSA



Phynova Group plc (AIM: PYN), the developer of prescription pharmaceuticals
derived from Chinese botanical medicines, today announces that its Business
Development Director, Dr Tony Mills, will provide an update on its plant-derived
antibacterial PYN6 at the natural products conference "Natural Products in Drug
Discovery and Development" at the Holiday Inn, Munich City Centre on Tuesday, 4
December. Results from pre-clinical work conducted by Phynova in collaboration
with the University of East London have demonstrated a high degree of bacterial
inhibition against 30 common strains of methicillin-resistant Staphylococcus
aureus (MRSA) isolated from London's teaching hospitals. Inhibition was
demonstrated against all of the strains of MRSA that were tested, using levels
of PYN6 that were some tenfold less than that typically needed to achieve
inhibition with mupirocin, the topical antibiotic currently routinely used for
treatment of skin infections involving MRSA. Furthermore resistance to PYN6 has
not been observed even after prolonged culture of numerous MRSA strains with
PYN6. PYN6 has also shown significant activity against the Propionibacterium
acnes organism which causes acne.

Phynova is conducting formulation studies to develop a topical gel, cream or
ointment containing PYN6 as active ingredient and is in active discussions with
several companies in the dermatological sector regarding the future development
and commercialisation of PYN6.

Robert Miller, Phynova's CEO, said: "Gaining access to potentially valuable new
drug opportunities such as PYN6 was an important part of the rationale for our
cooperation with our Chinese partner Botanic Century. We are delighted that the
extensive preclinical work that we have carried out this year has confirmed its
promise as a potential treatment for MRSA, the devastating bacterial infection
that has become such a problem in the UK. An additional key part of our
commercial strategy is to offer a proportion of our drug candidates as in
licensing opportunities to the pharma industry so we are also very pleased with
the interest that we are attracting from potential partners."

                                    - Ends -

For further information, please contact:


Phynova Group PLC                                         +44 (0) 1993 880700
Robert Miller, Chief Executive Officer                         www.phynova.com

Nominated Adviser:
Nabarro Wells & Co. Limited                               +44 (0) 20 7710 7400
Marc Cramsie/Harry Stockdale

Broker:
Evolution Securities China Limited                        +44 (0) 20 7220 4850
Barry Saint



Media enquiries:
Abchurch Communications                                   +44 (0) 20 7398 7700
Peter Laing/Ashley Tapp
ashley.tapp@abchurch-group.com                          www.abchurch-group.com



Notes to Editors:



About Phynova

Phynova is a UK company developing prescription pharmaceuticals derived from
Chinese botanical medicines. Phynova is focused on viral and metabolic diseases
and cancer. Phynova's lead product for hepatitis C has now completed a Phase I/
II trial in the US and the Phase IIb trial is scheduled to commence in the first
half of 2008. Two further products, for fatty liver disease and post-operative
ileus, are targeted for entry to the clinic over the next six months and there
are a further four products in preclinical development.



About MRSA and Phynova's clinical candidate antibacterial PYN6

Every year an estimated 100,000 UK patients contract an antibiotic-resistant
infection while in hospital. Cases of MRSA in England and Wales have increased
by 600% in the last decade. The reported cost to the NHS of treating these
infections is already believed to exceed #1 billion a year. With the steep
increase in the appearance of so-called "super-bugs" such as MRSA in UK
hospitals, there is a widely-recognised need for new anti-bacterial treatments.

The majority of strains of MSRA are resistant to a wide range of antibiotics,
including some of those most recently introduced. Some strains are also
resistant to antibiotics such as mupirocin, a topical antibiotic currently used
to combat asymptomatic carriage and colonisation in hospitals. In some hospital
intensive care units, it is estimated that as many as 10-20% of patients may be
colonised by MRSA. Mupirocin is currently the most widely-used conventional
topical antibiotic for MRSA infections but there is increasing evidence of
resistance emerging to this agent, especially in the hospital setting.

PYN6 is a plant extract antibacterial that was licensed from Phynova's Chinese
affiliate Botanic Century in November 2006. Botanic Century had tested PYN6 in
in vitro assays against a wide spectrum of bacterial species (including MRSA)
that have become resistant to commonly-used antibiotics. PYN6 was found to be a
potent antibiotic against all species tested. These results have since been
confirmed and extended by Phynova. Furthermore it has proved exceptionally
difficult to induce resistance to PYN6 by repeated culture at sub-lethal dose
levels - a process that rapidly leads to the emergence of resistant strains with
most antibiotics currently used against MRSA, such as the quinolone antibiotic
ciprofloxacin.

PYN6 is an active fraction isolated from a single plant species used in
traditional Chinese medicine. Both the composition of the fraction and the
extraction process are proprietary to Phynova. Phynova plans to find partners
for the future development and commercialisation of PYN6 in both the MRSA and
acne indications.

For further information please visit www.phynova.com;




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCURSNRBBRAOAA

Phynova (LSE:PYN)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

Phynova (LSE:PYN)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025